Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02
April 23, 2014 at 08:02 AM EDT
Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, ...